As a global health care company, we improve access to affordable, high-quality health care in many countries:
- Every 0.7 seconds, Fresenius Medical Care provides a dialysis treatment somewhere around the globe.
- With a broad range of generic products, Fresenius Kabi enables patients with medical needs to access modern therapies and affordable health care.
- In the past five years, Fresenius Helios has invested more than €1 billion in the modernization and development of clinical services in Germany and Spain and thereby contributes to comprehensive high-quality health care.
- Fresenius Vamed has completed more than 900 projects in around 90 countries, many of these in regions in which the development of health care infrastructure is still at an early stage. Through this, Fresenius Vamed contributes decisively to facilitating access to health care facilities for patients.
How we contribute
We are committed to respecting and supporting human rights as they are defined by international standards, such as the United Nations Universal Declaration of Human Rights and the Fundamental Principles as published by the International Labor Organization (ILO)1. We consider this part of our responsibility as a company.
In 2018, we have adopted a Group-wide statement regarding human rights. It contains aspects of human rights that are of special importance for Fresenius. Our activities serve to respect human rights and shall support their protection. We strive to continuously develop these activities.
For more information about our position see the Non-financial Report.
The human rights statement is a self-commitment, which is valid for all business segments and Fresenius SE & Co. KGaA. It complements the commitments and principles regarding respecting human rights, which all business segments have included in their Codes of Conduct.
The safety of our patients is our priority. Worldwide, millions of them rely on the quality of our care. Therefore, the following applies for all business segments. When we recognize indications of deficiencies and limitations in our products, therapies, or processes, we make them transparent and take necessary actions. When conducting clinical studies, too, our first priority is the safety of our patients. We observe ethical, medical, and legal requirements. When we recognize any indications of deviations, we respond. We keep awareness of our values and principles of conduct up to date through regular classroom or online training on the respective Code of Conduct for our employees and managers.
Operational implementation and assessment of our activities are the responsibility of the respective functions within the business segments. Measures such as training on the Codes of Conduct or reporting mechanisms are supported by the Compliance Management Systems. You will find details on this in the chapter Doing the right thing. In addition, checks are also conducted as part of internal audits.
Employees of all business segments and Fresenius SE & Co. KGaA, as well as external partners can report potential violations, also related to human rights aspects, via whistleblower hotlines or e-mail addresses. In addition, employees can report their concerns directly to their superiors. Additional information on reporting possibilities is described in the chapter on the Compliance Management Systems. If we have information on potential violations, we take necessary measures.
We take the results of internal reviews and reports as an opportunity to review our company processes for improvements of our internal processes and implement corrective or improvement measures.
No events with a material adverse impact were recorded in the business year that conflict with our goal of respecting human rights.
For more information see the Non-financial Report.